典型文献
Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis
文献摘要：
Currently,nonalcoholic steatohepatitis(NASH)is one of the most common forms of chronic hepatitis,increasing the burden of health care worldwide.In patients with NASH,the fibrosis stage is the most predictive factor of long-term events.However,there are still no drugs approved by the Food and Drug Administration of the United States for treating biopsy-proven NASH with fibrosis or cirrhosis.Although some novel drugs have shown promise in preclinical studies and led to improvement in terms of hepatic fat content and steatohepatitis,a considerable proportion of them have failed to achieve histological endpoints of fibrosis improvement.Due to the large number of NASH patients and adverse clinical outcomes,the search for novel drugs is necessary.In this review,we discuss current definitions for the evaluation of treatment efficacy in fibrosis improvement for NASH patients,and we summarize novel agents in the pipeline from different mechanisms and phases of trial.We also critically review the challenges we face in the development of novel agents for fibrotic NASH and NASH cirrhosis.
文献关键词：
中图分类号：
作者姓名：
Yi-wen Shi;Jian-gao Fan
作者机构：
Center for Fatty Liver,Department of Gastroenterology,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai Key Lab of Pediatric Gastroenterology and Nutrition,Shanghai 200092,China
文献出处：
引用格式：
[1]Yi-wen Shi;Jian-gao Fan-.Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis)[J].中国药理学报（英文版）,2022(05):1191-1199
A类：
B类：
status,challenges,treatment,fibrotic,nonalcoholic,steatohepatitis,Currently,NASH,one,most,common,forms,chronic,increasing,burden,health,care,worldwide,In,patients,fibrosis,stage,predictive,long,events,However,there,still,drugs,approved,by,Food,Drug,Administration,United,States,treating,biopsy,proven,cirrhosis,Although,some,novel,have,shown,promise,preclinical,studies,improvement,terms,hepatic,fat,content,considerable,proportion,them,failed,achieve,histological,endpoints,Due,large,number,adverse,outcomes,search,necessary,this,review,discuss,current,definitions,evaluation,efficacy,summarize,agents,pipeline,from,different,mechanisms,phases,trial,We,also,critically,face,development
AB值：
0.560055
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
